[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://lyell.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 224, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 71, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 80000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 962226, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles W. Newton", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 744737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 775967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Lee Ph.D.", "age": 46, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Lang J.D.", "age": 47, "title": "Chief Business Officer, Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 596253, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 62, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.36, "open": 2.33, "dayLow": 2.12, "dayHigh": 2.34, "regularMarketPreviousClose": 2.36, "regularMarketOpen": 2.33, "regularMarketDayLow": 2.12, "regularMarketDayHigh": 2.34, "beta": -0.404, "forwardPE": -2.3846154, "volume": 612662, "regularMarketVolume": 612662, "averageVolume": 818341, "averageVolume10days": 799800, "averageDailyVolume10Day": 799800, "bid": 2.15, "ask": 2.21, "bidSize": 200, "askSize": 100, "marketCap": 553217664, "fiftyTwoWeekLow": 1.32, "fiftyTwoWeekHigh": 3.41, "priceToSalesTrailing12Months": 8135.5537, "fiftyDayAverage": 2.4986, "twoHundredDayAverage": 2.082475, "currency": "USD", "enterpriseValue": 88744112, "floatShares": 164219100, "sharesOutstanding": 254939008, "sharesShort": 20104934, "sharesShortPriorMonth": 18226808, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0789, "heldPercentInsiders": 0.154, "heldPercentInstitutions": 0.73234004, "shortRatio": 24.99, "shortPercentOfFloat": 0.1121, "bookValue": 2.366, "priceToBook": 0.9171598, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -228340000, "trailingEps": -0.9, "forwardEps": -0.91, "pegRatio": 0.34, "enterpriseToRevenue": 1305.06, "enterpriseToEbitda": -0.407, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LYEL", "underlyingSymbol": "LYEL", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "firstTradeDateEpochUtc": 1623936600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c5ad7970-8aa2-3c85-a7aa-1e907d8cc7ab", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.17, "targetHighPrice": 9.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.33, "targetMedianPrice": 6.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 526300000, "totalCashPerShare": 2.064, "ebitda": -218286000, "totalDebt": 61826000, "quickRatio": 16.267, "currentRatio": 16.511, "totalRevenue": 68000, "debtToEquity": 10.25, "returnOnAssets": -0.18935, "returnOnEquity": -0.32926, "freeCashflow": -84199128, "operatingCashflow": -159498000, "revenueGrowth": -0.954, "grossMargins": 1.0, "operatingMargins": -18530.0, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-18"}]